RATING

RECOMMENDATION

Sell

  • ROFR Required
  • Available in Depository:

  • NSDL

  • CDSL

  • Available for Investment:

  • Primary

  • Secondary

RATING

RECOMMENDATION

Sell

Business Type

Dominant Leader

RATING

RECOMMENDATION

Sell

Business Type

Dominant Leader

Pharmeasy Profit and Loss

  • Net Income

    The company has faced a net loss of INR 641 Cr in FY'21 which is almost double the loss face by the company in FY'20. The higher net loss is a result of increased inventory purchased as well as higher employee remuneration expenses. Another reason is the constant discounted prices of pharmaceuticals, the burden of which has to be borne by the company.

  • Revenue Growth

    The company has witnessed a massive revenue growth of 220% in FY'21 at INR 2,360 Cr. This is primarily due to the higher demand for pharmaceuticals and health care services due to the pandemic spreading all over the country.

Financial Year

Total Revenue
COGS
Gross Profit
Raw Materials
Power & Fuel Cost
Employee Cost
Sales & Administrative Expenses
Operating & Other Expenses
EBITDA
Depreciation/ Amortization
PBIT
Interest & Income
Interest & Expense
Other Items
PBT
Taxes & Other Items
Net Income
Diluted EPS
Basic EPS
DPS
Payout Ratio
FY 2020

737.45

-

737.45

640.89

-

137.19

-

275.67

-316.3

18.77

-335.07

-

11.89

-

-346.96

-11.68

-335.28

-129.15

-129.15

-

-

FY 2021

2,360.66

-

2,360.66

2,152.42

-

270.29

-

481.88

-543.93

32.9

-576.84

-

43.43

-

-620.27

21.07

-641.34

-206.77

-206.77

-

-

EPS and DPS in ₹. Other numbers except Payout Ratio in ₹ Cr

* denotes current year's data

  • Pharmeasy Annual Reports

2021

Jefferies Research report on API Holding(Pharmeasy).

API Holdings(Pharmeasy) DRHP